Eli Lilly and Co logo

Eli Lilly and Co

ARS 12778.00 (+2.33%) Oct 4
On watch
P/E:
53.64
P/B:
36.87
Market Cap:
ARS 46.46T ($ 312.67B)
Enterprise V:
ARS 48.55T ($ 326.71B)
Volume:
170.00
Avg Vol (2M):
317.00
Also Trade In:
Volume:
170.00
Market Cap ARS:
46.46T
Market Cap $:
312.67B
PE Ratio:
53.64
Avg Vol (2-Month):
317.00
Enterprise Value ARS:
48.55T
Enterprise Value $:
326.71B
PB Ratio:
36.87
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Financials (Next Earnings Date:2022-10-26 Est.)

BUE:LLY's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil ARS) 3,089,431.059
EPS (TTM) (ARS) 2615.64
Beta 0
Volatility % 36.95
14-Day RSI 63.36
14-Day ATR (ARS) 400.026227
20-Day SMA (ARS) 11770.575
12-1 Month Momentum % 107.65
52-Week Range (ARS) 5384 - 13894.5
Shares Outstanding (Mil) 237.54

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Eli Lilly and Co Filings

Document Form Filing Date
No Filing Data

Eli Lilly and Co Analysis

Share your research